Compare HOVR & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | ALGS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1M | 57.2M |
| IPO Year | N/A | 2020 |
| Metric | HOVR | ALGS |
|---|---|---|
| Price | $1.81 | $11.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.50 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 976.5K | 73.7K |
| Earning Date | 01-13-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $55.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $3.76 |
| 52 Week High | $4.18 | $46.80 |
| Indicator | HOVR | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 70.56 |
| Support Level | $1.70 | $9.10 |
| Resistance Level | $1.69 | $10.45 |
| Average True Range (ATR) | 0.14 | 0.66 |
| MACD | 0.07 | 0.28 |
| Stochastic Oscillator | 96.40 | 97.16 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.